$MannKind (MNKD.US)$ MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22
$MannKind (MNKD.US)$ MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®) 4 minutes ago, 3:05 AM PST Via GlobeNewswire Company plans to meet with FDA regarding potential sNDA submission in 1H 2025 Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression MannKind (MNKD) announced six-month results from its Phase 3 INHALE-1 study of Afrezza (inhaled insulin) in children and adolescents aged 4-17...
I think this company still has room to grow and may be undervalued, however it is next to being scaling out for other opportunities as the space is crowded and many new therapies have advanced.
I think$United Natural Foods (UNFI.US)$ is still undervalued. Originally purchased as a longterm hold, I intend to sell instead at ~25 USD and put the capital toward other trades, likely CSPs focusing on other equities for longterm holds. A speculative hold for the longterm, though may take profit if another opportunity beckons. This is the same approach as to$MannKind (MNKD.US)$and$Iovance Biotherapeutics (IOVA.US)$: Two speculative positions that I am building (similar ...
These calls performed well in theory, but I was unable to get a fill at maximum profit, which was about 90%. I’ve learned a realted lesson a few times. It’s key to trade options with a great deal of liquidity. (Or pay a fee for more obscure tickers, in order to get a more beneficial fill.) I now largely trade more popular contracts and use LEAPS to speculate in the longer term on less heavily traded equities; treating them as less capital intensive share proxies, to be traded at a ...
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
MannKind Stock Forum
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
4 minutes ago, 3:05 AM PST
Via GlobeNewswire
Company plans to meet with FDA regarding potential sNDA submission in 1H 2025
Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression
MannKind (MNKD) announced six-month results from its Phase 3 INHALE-1 study of Afrezza (inhaled insulin) in children and adolescents aged 4-17...
loading...
is still undervalued. Originally purchased as a longterm hold, I intend to sell instead at ~25 USD and put the capital toward other trades, likely CSPs focusing on other equities for longterm holds.
A speculative hold for the longterm, though may take profit if another opportunity beckons. This is the same approach as to $MannKind (MNKD.US)$ and $Iovance Biotherapeutics (IOVA.US)$ :
Two speculative positions that I am building (similar ...
loading...
No comment yet